our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
RPL22L1 overexpression
i
Other names: RPL22L1, Ribosomal Protein L22 Like 1, Large Ribosomal Subunit Protein EL22-Like 1, 60S Ribosomal Protein L22-Like 1, Ribosomal Protein L22-Like 1
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Our study identified a novel candidate oncogene RPL22L1 which promoted the GBM malignancy through STAT3 pathway. And we highlighted that Stattic combined with TMZ therapy might be an effective treatment strategy in RPL22L1 high-expressed GBM patients.
4 months ago
Journal
|
STAT3 (Signal Transducer And Activator Of Transcription 3) • RPL22L1 (Ribosomal Protein L22 Like 1) • RPL22 (Ribosomal Protein L22)
We demonstrated that high RPL22L1 expression is significantly associated with breast cancer, particularly in TNBC. Loss of RPL22L1 expression in carcinoma with medullary pattern highly indicates that medullary carcinoma is a pathologically and biologically distinct subtype of invasive breast carcinoma. Our findings suggest that RPL22L1 may be a novel and valuable biomarker for the pathogenesis and classification of TNBC.
7 months ago
RPL22L1 (Ribosomal Protein L22 Like 1) • RPL22 (Ribosomal Protein L22)
Furthermore, higher RPL22L1 expression can also promote cell proliferation and epithelial-mesenchymal-transition, as well as drug resistance to 5-Fluorouracil (5-FU) and cisplatin (CDDP). The expression of RPL22L1 was also associated with adverse prognosis in HCC clinical samples. In conclusion, our study reveals aberrant ribosomal protein activity in HCC and the role of RPL22L1 in promoting HCC tumor progression.
1 year ago
Cancer stem
|
SOX9 (SRY-Box Transcription Factor 9) • RPL22L1 (Ribosomal Protein L22 Like 1)
Importantly, the ERK inhibitor (ERKi) could potentiate sorafenib efficiency in RPL22L1-high HCC cells. In summary, these data uncover RPL22L1 is a potential marker to guide precision therapy for utilizing ERKi to enhance the sorafenib efficacy in RPL22L1-high HCC patients.
Our results showed that ONT-identified genes provide a pool to explore AS-associated markers for dMMR/MSI CRC. We demonstrated INHBA as a promising signature for clinical application in predicting tumor lymphatic metastasis and screening dMMR/MSI candidates.
over 1 year ago
Journal • Mismatch repair
|
MSI (Microsatellite instability) • RPL22L1 (Ribosomal Protein L22 Like 1) • HMGCS2 (3-Hydroxy-3-Methylglutaryl-CoA Synthase 2)